ALIDA ASKREN: Open Payments
NPI 1225787013 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 45 payments from 20 companies in 2025. Trend: 2023 $29 · 2024 $390 · 2025 $870
Food & beverage: $870
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $155 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $126 |
| Lilly USA, LLC | 4 | $81 |
| GlaxoSmithKline, LLC. | 4 | $71 |
| Antares Pharma, Inc. | 3 | $49 |
| Exact Sciences Corporation | 3 | $48 |
| Averitas Pharma Inc. | 2 | $40 |
| PFIZER INC. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
Products named: Kerendia, MOUNJARO, Ozempic, Rybelsus, TRELEGY ELLIPTA, XYOSTED, QUTENZA, ELIQUIS.
Industry payments across TX — which companies pay providers there.
